ColostrumTrust Score: 40
Sovereign Laboratories
Facts-only compliance record. Every entry is source-backed and dated.
Last reviewed: 2026-04-15
2Critical
1Moderate
Event Timeline
GapModerate
Limited public testing documentation
Limited publicly available testing documentation identified as of April 2026. Phase 2 research pending for full regulatory and testing gap assessment.
FDACritical
Joint FDA/FTC warning: marketing colostrum products as COVID-19 treatments
Joint FDA/FTC warning letter for marketing PRO Colostrum-LD, Colostrum-LD, PRO Vital C-LD, and Vital C-LD as COVID-19 treatments and preventatives. Products deemed misbranded drugs violating the FD&C Act. Second federal warning letter in 18 months.
FDACritical
FDA warning letter: drug claims for Colostrum-LD, Viralox, and Curcumin-LD
FDA warned Sovereign Laboratories about Colostrum-LD, Viralox, and Curcumin-LD making drug claims — marketing products as cures/treatments for infections, viruses including Herpes and Influenza. Products deemed unapproved drugs under the FD&C Act.